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Synthesis of 11C-labeled Sulfonyl Carbamates through
a Multicomponent Reaction Employing Sulfonyl Azides,
Alcohols, and [11C]CO
Marc Y. Stevens,[a] Shiao Y. Chow,[a] Sergio Estrada,[b] Jonas Eriksson,[c] Veronika Asplund,[b]
Anna Orlova,[c] Bogdan Mitran,[c] Gunnar Antoni,[c] Mats Larhed,[d] Ola aberg,[b] and
Luke R. Odell*[a]
1. Introduction
The sulfonyl carbamate functional group is an easily accessible
carboxylic acid bioisostere, and is traditionally introduced in
the N-acylation of sulfonamides with carbonic acid derivatives
such as chloroformate or anhydride.[1] Sulfonyl carbamates are
also used as nitrogen nucleophiles in the Mitsonobu reaction,[2]
as protecting groups for alcohols[3] and as dehydrating re-
agents.[4] The sulfonyl carbamate moiety can be found in mole-
cules with anticancer,[5] herbicidal,[6] lipid-regulating,[7] and anti-
bacterial[8] properties. Furthermore, it is present in a plethora
of ligands[9] to the angiotensin II subtype 1 and 2 receptors
(AT1R and AT2R, respectively), a subject of ongoing research in-
terest in our laboratory.[10] Compound 21 (C21, see Scheme 1),
the first non-peptide AT2R selective agonist,
[11] is currently in
clinical trials for the treatment of idiopathic pulmonary fibrosis
and has been the subject of intense study since its disclo-
sure.[12] In addition to its beneficial effects in animal models of
cardiovascular disorders,[13] stroke,[14] and spinal cord injury,[15]
C21 represents a possible therapeutic alternative in the man-
agement of prostate cancer, the leading cause of cancer in Eu-
ropean men.[16,17] As AT2R expression has been shown to de-
crease with disease progression, we envisioned that the use of
a radio-labeled selective non-peptide AT2R agonist would pro-
vide a potential means for the monitoring and staging of pros-
Scheme 1. Representative sulfonyl carbamates, including C21—the first non-
peptide angiotensin II receptor subtype 2 agonist.
We describe the development of a new methodology focusing
on 11C-labeling of sulfonyl carbamates in a multicomponent re-
action comprised of a sulfonyl azide, an alkyl alcohol, and
[11C]CO. A number of 11C-labeled sulfonyl carbamates were syn-
thesized and isolated, and the developed methodology was
then applied in the preparation of a biologically active mole-
cule. The target compound was obtained in 24:10% isolated
radiochemical yield and was evaluated for binding properties
in a tumor cell assay; in vivo biodistribution and imaging stud-
ies were also performed. This represents the first successful ra-
diolabeling of a non-peptide angiotensin II receptor subtype 2
agonist, C21, currently in clinical trials for the treatment of idio-
pathic pulmonary fibrosis.
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tate cancer, as well of investigating AT2R function and the
in vivo properties of non-labeled C21.
The use of positron emission tomography (PET) allows non-
invasive visualization of biological processes at the molecular
or cellular level.[18,19] This is achieved by the incorporation of
a short-lived radionuclide such as 11C (t1/2=20.4 min) into an
organic molecule, which can then be administered as a tracer.
To this end, several classes of non-peptide AT2R ligands have
previously been reported by Hallberg and co-workers[11,20–22]
and a 11C-labeled benzamide ligand was evaluated for tracer
properties and biodistribution.[23] Although the ligand tested
did not display favorable metabolic properties, we wished to
extend this work to include C21, the most potent and well-
studied ligand to this receptor. To the best of our knowledge,
there is no existing methodology for the preparation of 11C-la-
beled sulfonyl carbamates. We, therefore, turned our efforts to
the development of a general methodology that would enable
synthesis, purification, and formulation of 11C-sulfonyl carba-
mates within the time constraints induced by our radionuclide
of choice. This methodology could then be applied to the
preparation of 11C-labeled C21 ([11C]C21).
Having identified a suitable target compound, we envi-
sioned a multicomponent[24] approach to the synthesis of
[11C]C21 containing a 11C-labeled sulfonyl carbamate moiety,
starting from the corresponding sulfonyl azide. A retrosynthet-
ic analysis revealed two possible precursor molecules that
could be used in the preparation of 11C-sulfonyl carbamates
(Scheme 2). Although elegant use has been made of [11C]CO2
in the direct synthesis of carbamates from amines and alkyl
halides,[25] to the best of our knowledge, this methodology has
not been tested with sulfonamides as the nucleophilic compo-
nent (route A). RhI-mediated carbonylation chemistry, on the
other hand, is well-suited to radionuclide incorporation by
using sulfonyl azides and [11C]CO (route B).[26] We, therefore,
chose to expand the scope of carbonylation chemistry, em-
ploying a sulfonyl azide and an alcohol as the nucleophilic
component. Relying on recently disclosed methodology that
enables confinement of [11C]CO in small-volume reaction ves-
sels at low pressure by using soluble xenon as the transfer
gas,[27] we sought to develop a synthetic route to 11C-labeled
sulfonyl carbamates. The potential of multicomponent reac-
tions in terms of robustness and operational simplicity would
then be harnessed to afford rapid access to structurally diverse
11C-carbamates. Herein, we describe the development of
a novel method of preparing 11C-sufonyl carbamates and its
application in the synthesis of [11C]C21.
2. Results and Discussion
2.1. Model Carbamates
By using chemistry developed in our group,[28, 29] a number of
sulfonyl azide precursors were prepared and converted to the
corresponding isotopically unmodified sulfonyl carbamates,
which were then used as analytical standards. With previous
work on aryl azides[30] and sulfonyl azides[26] as entry points, we
carried out a preliminary screening of reaction conditions
(Table 1) for the synthesis of 11C-sulfonyl carbamates, using
thiophene-2-sulfonyl azide (1a) as a model substrate. Inspired
by the efforts of Long and Ning,[31] we began our catalyst
screen with PdCl2, a readily available and inexpensive catalyst.
However, it quickly became apparent that PdCl2 was not ame-
nable to the scale on which 11C-labeling reactions are normally
conducted. The poor solubility of PdCl2 in selected solvents
(DMA, DMF and THF) hindered the preparation of stock solu-
tions, and it was observed to catalyze the formation of multi-
ple 11C-labeled side products (Table 1, entries 1 and 2). Decreas-
ing the concentration of PdCl2 and increasing reaction temper-
ature led to an improvement in both the conversion of [11C]CO
to non-volatile components (conversion), as well as a concomi-
tant increase in non-isolated radiochemical yield (NIRCY)
(entry 2). The difficulties encountered when working with PdCl2
and its propensity to oxidize CO to CO2 in the presence of
Scheme 2. Retrosynthetic approach to 11C-labeled carbamates.
Table 1. Catalyst and ligand effect on formation of 2a from 1a.[a]
Entry [Cat] [Lig] T
[8C]
[Nu] Conv.
[%][b]
RCY
[%][c]
1 A, 10 – 75 80 9 6
2 A, 2 – 100 110 68 50
3 B, 3 – 100 80 82 66
4 B, 3 – 110 80 54–61 33–35[d,e]
5 B, 3 – 120 80 18 3
6 C, 0.4 – 100 80 48 39–43[d]
7 D, 0.4 PPh3, 1.2 75 80 95 86 (46)
[e]
8 D, 0.4 PPh3,1.2 100 80 89 75–82
[d]
9 D, 0.4 PPh3,1.2 120 80 14 11
10 D, 0.4 PPh3, 2.4 100 80 94 88 (55)
[e]
11 D, 0.4 Xantphos, 1.2 100 80 50 20[e]
12 D, 0.4 dppf, 1.2 100 80 92 56
13 D, 0.4 dppp, 1.2 100 80 52 38–48[d]
[a] Catalyst, ligand, and n-butanol in stock solutions. All reactions carried
out in 1 mL pear-shaped vial with crimp cap under argon, final volume
0.3 mL, concentrations in mM, [1a]=40 mm for all entries except for
entry 2 (50 mm). [b] Conversion, percentage of non-volatile activity re-
maining in reaction solution after flushing with N2, see Figure S1. [c] Non-
isolated radiochemical yield, decay-corrected. [d] n=2. [e] Isolated radio-
chemical yield. A=PdCl2, B=Pd(PPh3)4, C=Pd(OAc)2, D= [Rh(COD)Cl]2.
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water[32] led us to select Pd(PPh3)4, a common choice for transi-
tion-metal-mediated 11C-carbonylation reactions.[23,33,34] We
were pleased to see a relatively large increase in conversion
and NIRCY (entry 3), but increasing the temperature had a det-
rimental effect on both conversion and NIRCY (entries 4 and 5).
Pd(OAc)2 has been used
[35] in the synthesis of sulfonylureas
from the corresponding sulfonyl chlorides and CO, but a con-
version of 48% and a non-isolated radiochemical yield of 43%
prompted us to investigate RhI as a catalyst. Earlier work[26] in
our group demonstrated the utility of RhI in aminocarbonyla-
tion reactions of sulfonyl azides, and [Rh(COD)Cl]2 and PPh3 at
75 8C gave a conversion of 95% and an NIRCY of 86%
(entry 7). Increasing the temperature to 100 8C gave similar re-
sults, but increasing to 120 8C had a negative impact on both
conversion and NIRCY (entries 8 and 9). Increasing the concen-
tration of PPh3 to achieve a P/Rh ratio of 3:1 in order to form
the Wilkinson’s catalyst[36] gave a comparable conversion and
an NIRCY of 88% (entry 10), leading us to select these condi-
tions. Moreover, we were pleased by the superior performance
of the ubiquitous PPh3 compared to bidentate ligands of vary-
ing bite angles (Xantphos, dppf, and dppp; entries 11–13).
Having demonstrated the viability of this strategy, we then
applied it to the synthesis of a variety of functionalized 11C-la-
beled sulfonyl carbamates (Table 2). We began by investigating
the scope of the alcohol component, using p-toluene sulfonyl
azide (tosyl azide, TsN3, 1b) as the azide scaffold. Gratifyingly,
n-butanol performed well with TsN3, forming
11C-sulfonyl carba-
mate 2b in a slightly lower isolated yield as compared to thio-
phene-2-sulfonyl azide. Secondary alcohols gave comparable
yields (2c and 2d), but the use of benzyl alcohol resulted in
a lower isolated radiochemical yield, despite good conversion
of gaseous [11C]CO (2e). 2-Thiophenemethanol gave an isolat-
ed radiochemical yield of 23% (2 f), whereas hindered alcohols
gave low, albeit isolable yields (2g, 2h), and in the case of 2g,
a number of unidentified labeled side products were observed.
Having explored the scope of alcohols that could be used in
this reaction, we then investigated a number of sulfonyl azides
(Table 3). We were pleased to observe the compatibility of
structurally diverse sulfonyl azides with our reaction system.
Electron-rich and electron-poor arylsulfonyl azides gave com-
parable isolated radiochemical yields (3a and 3b) with slightly
lower conversion of gaseous [11C]CO as compared to TsN3. No-
tably, the use of a sulfonyl azide on an sp3 carbon gave good
conversion and an isolated radiochemical yield of 51% (3c).
This observation is in agreement with our results when using
isotopically unmodified CO and PdCl2.
[28] The use of a heteroaryl
sulfonyl azide gave a reduced, albeit isolable yield (3d), and in
the case of 3e, we were pleased to see a conversion of 85%
and a non-isolated radiochemical yield of 71%.
Inspired by the work of Collins and Glorius,[37] we then
tested the susceptibility of our reaction manifold to several po-
tential contaminants and other detrimental factors (Table 3). To
our surprise, the presence of both a free carboxylic acid and
a basic nitrogen center that could potentially interfere with
metal catalysts was tolerated (albeit with the formation of sev-
eral 11C-labeled side products ; Table 3, entry 1). Similarly, a non-
isolated radiochemical yield of 50% was observed when using
phenylacetylene as an additive (entry 2). This indicated that
the sulfonyl azide starting material was available for reaction,
despite its ability to undergo azide–alkyne cycloaddition.[38]
Conversely, the addition of excess H2O proved to be detrimen-
tal, as did the omission of catalyst (entries 3 and 4). Finally, the
use of 24 h old stock solutions exposed to light resulted in
a non-isolated radiochemical yield of 6%, most probably
owing to catalyst decomposition (entry 5).
Table 3. Robustness screen of the radiosynthesis of 2a from 1a[a]
Entry Additive/change Conv. [%] RCY[b] [%]
1 picolinic acid, 120 mm 77 50
2 phenylacetylene, 120 mm 52 50
3 H2O, 440 mm 7 4
4 no catalyst 5 4
5 old stock solutions[c] 14 6
[a] Reaction conditions: see Table 1, entry 10. [b] Determined by radio-
HPLC. [c] 24 h old previously-used stock solutions stored in 1 mL flat-bot-
tomed vials in anhydrous THF under N2 atmosphere.
Table 2. Azide and alcohol scope in multicomponent assembly of 11C-la-
beled sulfonyl carbamates[a]
2b, 55% (88%) 2c, 57% (77%) 2d, 45% (87%)
2e, 23% (75%) 2 f, 23% (60%)
2g, 3% (62%)
2h, 2% (33%) 3a, 40% (68%) 3b, 37% (65%)
3c, 51% (75%)
3d, 12% (42%) 3e, 71%[b] (85%)
[a] Isolated yields, decay-corrected, based on activity remaining after N2
purge (conversion, percentage of non-volatile products formed from
[11C]CO). [b] Non-isolated radiochemical yield. See Table 1, entry 9 for re-
actant concentrations.
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2.2. Synthesis of Key Sulfonyl Azide Precursor
Following route B, the key sulfonyl azide precursor 1n was pre-
pared in five steps, starting from the commercially available
tert-butyl sulfonamide 1h (Scheme 3). Treatment of 1h with
excess nBuLi followed by 1-bromo-2-methylpropane afforded
the 5-alkylated product 1 I, and subsequent lithiation and bory-
lation led to boronic acid 1 i. This was then subjected to
a Suzuki–Miyaura[39] cross-coupling reaction with imidazole de-
rivative 1 j, synthesized from 4-bromobenzyl bromide, to give
1 l. After deprotection with neat TFA, the primary sulfonamide
1m was converted into key sulfonyl azide precursor 1n
through a diazotransfer from an imidazole-1-sulfonyl azide salt,
demonstrating the utility of this methodology for late-stage
azidation.[29,40]
2.3. Preparation of [11C]C21
With precursor 1n in hand, we then turned our attention to
the preparation of [11C]C21 (see Scheme 4). Following our
newly-developed protocol, [11C]C21 was isolated in 24:10%
radiochemical yield (decay-corrected, n=9) and the specific ac-
tivity after [11C]CO introduction was 34–51 GBqmmol@1 (n=3).
Gratifyingly, the synthesis of [11C]C21 was robust and multiple
batches could be prepared for biological evaluation and imag-
ing purposes.
2.4. In Vitro Binding Specificity
The DU145 cell line (a brain metastasis of human prostate car-
cinoma[41]) was chosen for evaluation of the in vitro binding
characteristics of [11C]C21. Measured activity was significantly
lower in samples that were pre-incubated with non-labeled
C21, indicating specific binding (see Figure 1). As demonstrat-
ed by Guimond et al. ,[16] the presence of AT2R in non-tumoral
prostate tissue and early-stage prostate tumors suggests limit-
ed proliferation. A radiolabeled imaging agent could, therefore,
be used to stage disease progression and aid in the provision
of individualized therapy.
2.5. Biodistribution
Having demonstrated the in vitro utility of [11C]C21, we then
wished to evaluate its in vivo biodistribution in rats and poten-
tial as a PET tracer. To evaluate the kinetics of [11C]C21 in vivo,
biodistribution studies were carried out in healthy female rats.
Results from ex vivo organ distribution are shown as standar-
dized uptake values (SUVs) in Figure 2. The radioactivity rapidly
disappeared from blood, as evidenced by SUV values of ap-
proximately 0.3 within 10 min post-injection. The highest
uptake of radioactivity was observed in the liver, kidneys, and
Scheme 3. Precursor synthesis. Reagents and conditions: a) KOH, imidazole,
DMF, reflux, 16 h; b) nBuLi, THF, @78 8C (i), 1-bromo-2-methylpropane, r.t.
16 h (ii) ; c) nBuLi, THF, @78 8C (i), B(OiPr)3, r.t. 16 h (ii) ; d) 1 j, Pd(PPh3)4, NaOH
(aq), toluene, reflux, 3 h; e) TFA, 16 h; f) imidazole-1-sulfonyl azide hydrogen
sulphate, iPrOH/H2O, K2CO3, r.t. , 20 h.
Scheme 4. Preparation of [11C]C21 from 1n.
Figure 1. Specific binding of [11C]C21 to DU145 cells. For the pre-saturation
of receptors, an excess of non-radioactive C21 was added. Data are present-
ed as mean values from three samples:SD.
Figure 2. Organ uptake of [11C]C21 in healthy female rats. BL–blood; HE–
heart ; LU–lungs; LI–liver ; PA–pancreas; SP–spleen; AD–adrenals ; KI–kidneys;
INS—small intestine without contents; INS+–small intestine with contents;
INL—large intestine without contents; OV–ovaries; MU–muscle; BR–brain.
Data are presented as mean values and error bars represent the SD.
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intestine with contents that, in conjunction with rapid clear-
ance from blood, indicate fast elimination kinetics. Very low
levels of activity were detected in all other organs. Although
the AT2R has been previously detected in the pancreas and
sexual organs,[42] only low activity was detected in these
organs.
2.6. MicroPET-CT
The fused PET/CT images over the abdomen showed the same
distribution pattern for the anaesthetized male rats (Figure 3)
as that determined by ex vivo biodistribution studies when
using un-sedated female rats. The only organ that was clearly
distinguishable was the liver. However, by using early frames,
regions of interest (ROIs) could be drawn also for the aorta
and the left kidney, and time activity curves were generated.
The kinetics of [11C]C21 in these organs are shown in Figure S4
in the Supporting Information.
3. Conclusions
A general methodology for the 11C-labeling of sulfonyl carba-
mates in a RhI-mediated multicomponent reaction has been
developed and demonstrated by the preparation of 12 11C-sul-
fonyl carbamates. The radiolabeling of a potent, non-peptide
AT2R agonist (C21) was then successfully performed and the
isolated compound was found to bind specifically in prostate
tumor cells expressing AT2R. The biological evaluation of
[11C]C21 indicates rapid metabolism and excretion, thus pre-
cluding its use as a PET tracer. However, given the potential
utility of an AT2R-selective imaging agent in individualized
management of prostate cancer therapy, these results provide
an entry point into the development of future tracers to meet
this need.
Experimental Section
Chemistry
General
All reagents were purchased at the highest commercial quality and
used without further purification. Solvents used for extraction and
silica gel chromatography (EtOAc, hexanes, n-pentane, dichlorome-
thane and methanol) were used without purification or desicca-
tion. Yields are for isolated and spectroscopically pure material,
unless otherwise stated. Reaction progress was monitored by
using thin-layer chromatography (0.25 mm E. Merck silica plates,
60F-254), visualized by fluorescence quenching with UV light at
254 nm or by iodine staining. Silica gel chromatography was car-
ried out by using E. Merck silica gel (60 a pore size, particle size
40–63 nm). 1H NMR spectra were recorded at 400 MHz and
13C NMR spectra at 100 MHz by using a Bruker Avance III NMR
spectrometer. The chemical shifts for 1H NMR and 13C NMR were
referenced to TMS through residual solvent signals (1H, CDCl3 at
7.26 ppm; 13C, CDCl3 at 77.16 ppm;
1H, [D6]DMSO at 2.45 ppm;
13C,
[D6]DMSO at 39.43 ppm). LC–MS was performed on an instrument
equipped with a CP-Sil 8 CB capillary column (50V3.0 mm, particle
size 2.6 mm, pore size 100 a), operating at an ionization potential
of 70 eV, using a 2 min 5–100% CH3CN/H2O gradient (0.05%
HCOOH in both CH3CN & H2O). Accurate mass values were deter-
mined by using an electrospray ionization source with a 7-T hybrid
ion trap and a TOF detector or through chemical ionization by
using ammonia as carrier gas. Sulfonyl azides 1a–1g,[29] precursors
1h–1 l,[11] and the non-labeled standards for compounds 2a–2h
and 3a–3d[28] were synthesized following the literature procedures
and spectral data were in agreement with published values.
3-[4-[(1H-Imidazol-1-yl)methyl]phenyl]-5-isobutylthiophene-
2-sulfonamide (1m)
1 l (0.29 g, 0.68 mmol) was dissolved in 2 mL TFA and stirred over-
night at ambient temperature. Upon full consumption of starting
material (as confirmed by LC–MS), the volatiles were evaporated.
The crude product (colorless oil) was used in the next step without
further purification (0.25 g, 89%). Rf (SiO2)=0.24 (1:9 MeOH/DCM);
1H NMR (400 MHz, [D6]DMSO): d=9.14 (d, J=1.3 Hz, 1H), 7.82–7.74
(m, 1H), 7.65–7.62 (m, 4H), 7.62–7.60 (m, 1H), 7.48–7.38 (m, 2H),
6.91 (t, J=0.8 Hz, 1H), 5.45 (s, 2H), 2.68 (dd, J=7.0, 0.8 Hz, 2H),
1.99–1.80 (m, 1H), 0.94 ppm (d, J=6.6 Hz, 6H); 13C NMR (100 MHz,
[D6]DMSO): d=146.6, 141.8, 137.9, 136.2, 135.4, 135.1, 130.13,
130.08, 128.2, 122.3, 121.9, 51.5, 38.5, 30.4, 22.4 ppm; MS (ESI): m/z
calcd for C18H23N3O2S2 : 376.1153 [M+H
+] ; found: 376.1163.
3-[4-[(1H-Imidazol-1-yl)methyl]phenyl]-5-isobutylthiophene-
2-sulfonyl azide (1n)
To a stirred mixture of 1m (55.1 mg, 0.14 mmol) and K2CO3
(86.1 mg, 0.62 mmol) in 1:1 iPrOH/H2O (10 mL) was added imida-
zole-1-sulfonyl azide hydrogen sulfate (56.8 mg, 0.21 mmol). The
reaction mixture was stirred for 16 h and then quenched by the
addition of 10 mL NaHCO3. EtOAc (20 mL) was added and the re-
sulting aqueous phase was extracted with 20 mL EtOAc. The com-
bined organics were washed with brine, dried over Na2SO4, and
concentrated in vacuo. The crude yellow liquid obtained directly
after workup was of sufficient purity (ca. 2% starting material, as
confirmed by 1H NMR) to be used directly in RhI-mediated carbony-
lation chemistry. Purification by using silica gel chromatography
(0–10% MeOH in CHCl3) significantly reduced the isolated yield
(colorless liquid, 11 mg, 20%), possibly owing to stability issues
with the sulfonyl azide moiety. The purified compound was stable
for >1 month at @21 8C. Rf (SiO2)=0.32 (1:9 MeOH/DCM; 1H NMR
(400 MHz, CDCl3): d=7.49 (s, 1H), 7.33–7.22 (m, 2H), 7.03–6.98 (m,
2H), 6.91 (t, J=0.8 Hz, 1H), 6.72 (s, 1H), 6.63 (s, 1H), 4.98 (s, 2H),
2.51 (dd, J=7.1, 0.8 Hz, 2H), 1.82–1.58 (m, 1H), 0.78 ppm (d, J=
6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): d=153.8, 147.2, 136.1,
135.2, 134.1, 131.0, 130.9, 130.6, 128.5, 122.5, 121.1, 39.8, 31.1,
Figure 3. PET/CT image, showing in vivo distribution of [11C]C21 in a healthy
male rat. Grey scale (CT), 200–1500 Hounsfield units, colour scale (PET)
SUV=0 to 20 (black to red). White arrows show liver in 3 projections and
kidneys in transaxial projection.
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22.7 ppm; IR (KBr) 2170 cm@1; MS (ESI): m/z calcd for C18H20N5O2S2 :
402.1058 [M+H+] ; found: 402.1048.
Radiochemistry
General
All radiochemical work was carried out at Uppsala University Hos-
pital PET Centre. [11C]CO2 was produced by using a Scanditronix
MC-17 cyclotron through the 14N(p,a)11C nuclear reaction, whereby
the target gas (N2, containing 50 ppm O2) was bombarded with
17 MeV protons. Thereafter, the [11C]CO2 was transferred to the
low-pressure xenon system in a stream of helium gas. [11C]CO2 and
[11C]CO were concentrated on anhydrous silica gel at @196 8C. The
radioactive gases were released from both traps by removal of
liquid nitrogen containers and heating with coiled cable heaters.
Heated zinc (400 8C) was used to obtain [11C]CO from [11C]CO2.
When releasing the [11C]CO from the CO trap, the transfer gas was
changed from helium to xenon (+99.995%, 1.5 mLmin@1) and the
transfer needle was placed into the solvent in a sealed reaction
vial (Grace 11 mm silicon/PTFE septum, disposable). Analytical
radio-HPLC was carried out by using a VWR LaChrom ELITE system
(l-2130, l-2200, l-2400) equipped with a Merck Chromolith Per-
formance RP-18e column (4.6V100 mm). Method: 5–95% MeCN in
H2O (0.05% TFA), 10 min, 4 mLmin
@1. The UV signal was monitored
at 254 nm and radioactivity was monitored by using a Bioscan
Flow-Count PMT radioactivity detector. The 11C-labeled carbamates
were isolated through semi-preparative HPLC (VWR LaPrep HPLC
system P110, P311, equipped with a Reprosil Basic C18-HL column,
10V250 mm). Method: 5–95% MeCN in (NH4)2CO3 (pH 8.9),
8 mLmin@1. UV purity was monitored at 254 nm and radioactivity
was monitored by using a Bioscan Flow-Count PMT radioactivity
detector. All products were identified by co-elution with the corre-
sponding isotopically unmodified compound (prepared following
the literature procedure[28]) and were >95% radiochemically pure,
as confirmed by analytical radio-HPLC (see above). The identity of
[11C]C21 was further confirmed by radio-LC–MS (Waters Quattro
Premier Genesis C18 column, 4m particle size, 150 mmV4.6 mm, MS
running in selective ion recording ES+ mode) and radio-TLC carried
out on batches of [11C]C21 prepared for imaging. For radio-TLC,
a co-spot of isotopically unmodified C21 was run with the reaction
mixture and its retention was visualized by fluorescence quenching
(UV light, 254 nm). This value (in mm) was identical to that of the
labeled compound.
General Procedure for the Preparation of Stock Solutions of
Catalyst, Ligand, and Alcohol
Three oven-dried flat-bottomed vials (1 mL) were charged with cat-
alyst (2 mmol), ligand (14 mmol), or alcohol (48 mmol), respectively,
capped, and flushed with argon gas for 1 min. THF (1 mL, freshly
distilled over sodium metal, benzophenone indicator) was added
by using a Hamilton syringe, and argon gas was bubbled through
the resulting solution for 30 s. The vials were then vortexed for
5 min, after which all stock solutions were homogeneous. Prepared
stock solutions of the catalyst could be used for up to 12 h, after
which their color gradually changed from light yellow to yellow-
brown. Although all reactant vials were sealed and kept filled with
argon, atmospheric poisoning by water or oxygen cannot be ruled
out (see above for stability screen).
General Method for the Preparation of 11C-Sulfonyl
Carbamates 2a–2h and 3a–3d
An oven-dried conical vial (1 mL, PTFE/silicate crimp cap) was
charged with azide (12 mmol), capped, and flushed with argon gas
for 30 s. Catalyst and ligand (0.12 and 0.72 mmol, respectively) in
THF were added by using a Hamilton syringe and the reaction mix-
ture was diluted to a total volume of 300 mL with THF. Alcohol
(24 mmol in 50 mL THF) was added just prior to [11C]CO introduction
(typically 10–15 min after catalyst and ligand) to avoid potential
side reactions. [11C]CO was introduced into the reaction mixture
under a stream of xenon gas (see above) until measured activity
peaked. Thereafter, the reaction vial was placed in a heating block
for 5 min, after which activity (A0) was measured in a well-counter.
In a test reaction (n=3), the activity in the vial was checked direct-
ly after CO introduction and then after heating to see whether any
leakage had occurred. We were pleased to observe that all activity
remained in the vial. The reaction vial was then equipped with
a vent needle and flushed with a stream of nitrogen gas
(10 mLmin@1) for 30–60 s, and the remaining activity was measured
(see the Supporting Information for a discussion on the calculation
of the radiochemical yield). An aliquot (typically 1–5 mL) was taken
for crude HPLC analysis and comparison with an analytical stan-
dard.[28] In parallel, the reaction mixture was diluted with 100 mL
1:1 MeCN/H2O and purified by semi-preparative HPLC to give
2.2 GBq of sulfonyl carbamate 2a 52 min post EOB (decay-correct-
ed isolated RCY 55%), starting from 18 GBq [11C]CO. To ensure that
the recovery of activity was high and comparable throughout all
experiments, HPLC columns, injection ports, and reaction vials
were checked for residual activity after all preparative and analyti-
cal HPLC runs.
Butyl tosyl-[1-11C]carbamate (2b)
Prepared following the general procedure, starting from 24 GBq
[11C]CO, 6.4 GBq isolated 31 min post-EOB (decay-corrected IRCY
49%).
Isopropyl tosyl-[1-11C]carbamate (2c)
Prepared following the general procedure, starting from 12 GBq
[11C]CO, 2.5 GBq isolated 34 min post-EOB (decay-corrected IRCY
57%).
Cyclohexyl tosyl-[1-11C]carbamate (2d)
Prepared following the general procedure, starting from 13 GBq
[11C]CO, 2.7 GBq isolated 33 min post-EOB (decay-corrected IRCY
45%).
Benzyl tosyl-[1-11C]carbamate (2e)
Prepared following the general procedure, starting from 13 GBq
[11C]CO, 1.0 GBq isolated 40 min post-EOB (decay-corrected IRCY
23%).
Thiophen-2-ylmethyl tosyl-[1-11C]carbamate (2 f)
Prepared following the general procedure, starting from 19 GBq
[11C]CO, 2.0 GBq isolated 30 min post-EOB (decay-corrected IRCY
23%).
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(S)-2,3-Dihydro-1H-inden-1-yl tosyl-[1-11C]carbamate (2g)
Prepared following the general procedure, starting from 12 GBq
[11C]CO, 0.1 GBq isolated 38 min post-EOB (decay-corrected IRCY
3%).
tert-Butyl tosyl-[1-11C]carbamate (2h)
Prepared following the general procedure, starting from 16 GBq
[11C]CO, 0.1 GBq isolated 39 min post-EOB (decay-corrected IRCY
2%).
Butyl [(4-methoxyphenyl)sulfonyl]-[1-11C]carbamate (3a)
Prepared following the general procedure, starting from 12 GBq
[11C]CO, 1.7 GBq isolated 47 min post-EOB (decay-corrected IRCY
40%).
Butyl [(4-acetylphenylphenyl)sulfonyl)-[1-11C]carbamate (3b)
Prepared following the general procedure, starting from 12 GBq
[11C]CO, 1.8 GBq isolated 35 min post-EOB (decay-corrected IRCY
37%).
Butyl(benzylsulfonyl)-[1-11C]carbamate (3c)
Prepared following the general procedure, starting from 10 GBq
[11C]CO, 1.8 GBq isolated 43 min post-EOB (decay-corrected IRCY
51%).
Butyl [(6-chloropyridin-3-yl)sulfonyl)-[1-11C]carbamate (3d)
Prepared following the general procedure, starting from 10 GBq
[11C]CO, 0.2 GBq isolated 42 min post-EOB (decay-corrected IRCY
12%).
Butyl [(4-bromophenyl)sulfonyl)-[1-11C]carbamate (3e)
Prepared following the general procedure, selectivity 86%, conver-
sion 82% (decay-corrected NIRCY 71%).
Butyl [(3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-isobutyl-
thiophen-2-yl)sulfonyl)-[1-11C]carbamate ([11C]C21)
Prepared following the general procedure (see Table 1, entry 9). A
mixture of 1n, nBuOH, [11C]CO, [Rh(COD)Cl]2, and PPh3 in anhy-
drous THF was heated to 100 8C for 5 min. Purification of this mix-
ture with semi-preparative reversed-phase HPLC gave the title
compound. After reformulation in phosphate-buffered saline
(pH 7.4), the radiochemical purity was >95% with no detectable
amounts of reagents and starting materials present. The product
was radiochemically stable after 60 min at ambient temperature in
phosphate buffer.
Biological Evaluation
Animal Experiments
The animals used in this study were handled in accordance with
the guidelines set up by the Swedish Animal Welfare Agency and
were approved by the local animal ethics committee at Uppsala
(permit number: C11/15). For the biodistribution experiments,
healthy female Sprague Dawley rats weighing 300:80 g (mean:
SD) were used. The animals were housed in a ventilated and
thermo-regulated environment with a 12 h light/dark cycle and
were allowed free access to food and water.
Cell Lines
Cells were purchased from the American Type Tissue Culture Col-
lection (ATCC via LGC Promochem, Bor,s, Sweden). The cells were
cultured in RPMI media supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (PEST) and grown in
an incubator at 37 8C and 5% CO2. Trypsin–EDTA (0.25% trypsin,
0.02% EDTA in buffer, Biochrom AG, Berlin Germany) was used to
detach the cells. A solution of [11C]C21 (50 nm) was added to
plated cells. For blocking, 2 mm of non-labeled C21 was added
45 min before addition of the radiolabeled substance to saturate
the receptors. The cells were incubated for 30 min at 4 8C to pre-
vent internalization. Thereafter, the media was collected, the cells
were detached by using trypsin–EDTA solution (0.25% trypsin,
0.02% EDTA in buffer, Biochrom AG, Berlin, Germany), re-suspend-
ed, and the radioactivity in the cells and media was measured to
enable calculation of the fraction of cell-bound radioactivity. Ex-
periments were performed in triplicate. Data were assessed by
using an unpaired, two-sided t-test with GraphPad Prism (version
4.00 for Windows GraphPad Software) to determine significant dif-
ferences (p<0.05).
Biodistribution
The tissue distribution and kinetics of [11C]C21 were studied by
using healthy female Sprague–Dawley rats. Unsedated rats were in-
jected with formulated (phosphate buffer pH 7.4) [11C]C21 (11–
13 MBq) through a lateral tail vein as a bolus. The rats were eu-
thanized at defined time points by CO2–O2 inhalation. Selected
time points were 10 (n=2), 20, and 40 min post-injection (n=1 for
20 and 40 min). In total, blood and 13 organs were collected;
blood, heart, lungs, liver, pancreas, spleen, adrenals, kidneys, intes-
tines (with and without contents), ovaries, muscle, and brain. The
radioactivity and weight of all of the collected organs were mea-
sured and the injection site was checked for residual activity. The
organ uptake of [11C]C21 was expressed as SUVs, according to
Equation (1). RA (Bq/g) is the concentration of radioactivity in the
organ, InjRA (Bq) is the amount of radioactivity injected, and TBW
(g) is the total body weight of the animal. All radioactivity meas-
urements were corrected for decay.
SUV ¼ RA Bq=gð Þ
InjRA Bqð Þ=TBW gð Þ ð1Þ
Small-Animal PET
Two male Sprague–Dawley rats were anesthetized with isoflurane
(2–3%) in a 50/50% mixture of oxygen and air and placed on the
temperature-controlled bed of a small-animal PET/CT scanner (Tri-
umph trimodality, GE Healthcare). They were positioned with the
abdomen in the field of view. Thereafter, [11C]C21 (ca. 10 MBq) was
administered as a bolus injection in the tail vein and a dynamic
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PET scan was conducted for 40 min, followed by a CT scan. PET
data were reconstructed by using maximum likelihood estimation
maximization (10 iterations). Volumes of interest (VOIs) were drawn
manually in the averaged images, for the liver, and in early frames,
for the kidney and aorta. VOIs were then transferred to all frames
to generate time–activity curves.
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